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Abstract
Background: The well-known typical fusion gene BCR/ABL can be observed in connection with
a complex translocation event in only 2-10% of cases with chronic myeloid leukemia (CML). As
currently most CML cases are treated with Imatinib, variant rearrangements have in general no
specific prognostic significance, though the emergence of therapy resistance remains to be studied.
Results: Here we report an exceptional CML case with complex chromosomal aberrations not
observed before, involving a 5 chromosome translocation implying chromosomal regions such as
1q42, 4p14 and 5q31 besides 9q34 and 22q11.2.
Conclusion: The reported rearrangement developed most probably in one initial step and had no
influence on a good response during Imatinib treatment.
Introduction
Chronic myeloid leukemia (CML), a clonal myeloprolif-
erative disease is known to develop from a pluripotent
bone-marrow stem cell following the typical BCR and ABL
somatic gene rearrangement. In 90-95% of cases with
CML, the BCR/ABL fusion gene is the result of reciprocal
translocation between chromosomes 9 and 22 and is
cytogenetically observable as a small derivative chromo-
some 22 which is known as Philadelphia (Ph1) chromo-
some [1,2].
In a Ph-positive CML expression of the BCR/ABL chimeric
protein p210 with an increased tyrosine kinase activity is
essential for multiple signaling pathways to confer the
leukemia phenotype [3]. Imatinib mesylate (Glivec, for-
merly STI571) was designed specifically to inhibit the
tyrosine kinase activity of the bcr/abl protein and other
tyrosine kinases such as c-abl, c-kit and platelet-derived
growth factor receptor. By binding to an active site of the
tyrosine kinase, Imatinib mesylate switches off down-
stream signaling, cells stop proliferating and apoptosis
ensues [4]. Many studies have shown a high efficiency of
Imatinib therapy to achieve a complete or major cytoge-
netic response, i.e. 0-34% Ph-positive cells. This positive
effect may be achieved in cases with simple t(9;22), and
complex translocations resulting in a BCR/ABL fusion
gene, as well as in cases with cytogenetic clonal evolution
[5,6].
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Complex chromosomal rearrangements involving one or
more additional chromosomes were described in >600
cases with CML [7]. By conventional cytogenetic analysis,
two variant subgroups have traditionally been recognized:
complex, t(9;22;V), where V represents a third transloca-
tion partner chromosome and simple, t(9;V) or t(22;V)
[8]. Only in a few cases is a chromosomal fragment from
the third chromosome translocated to the der(22)t(9;22),
producing a 'masked Ph' [9]. In most Ph-variant cases the
segment 22q11->qter is moved to a third chromosome,
while a part of the third chromosome is located on 9q34.
Deletions on the derivative chromosome 9 were found to
occur with a much higher frequency in patients with vari-
ant Ph translocations (45%) than in those with classic Ph
(17%) [10].
Herein we report on a CML cases with new complex aber-
rations with five chromosomal breakpoints, nonetheless
successfully treatable by Imatinib.
Case report
The 45 year old female patient presented initially with a
whole blood cell count (WBC) of 43.500/l, splenomegaly
and severe loss of weight. Chromosome analysis using
banding cytogenetics only revealed a karyotype in con-
cordance with the clinical diagnosis of a CML in chronic
phase. She was treated with Hydroxyurea (1000 mg daily
dose).
Four years and four months later her WBC was 17.61 ×
109/l, i.e. 71.6% neutrophils, 18.9% lymphocytes, 3.1%
eosinophiles, 5.1% monocytes, 0.2% basophiles. Platelets
count was 650 × 109/l and hemoglobin 12.1 g/dl. She was
treated with Imatinib (400 mg daily dose) for overall 10
months. Then her WBC was 27.70 × 109/liter, i.e. 70.2%
neutrophils, 16.5% lymphocytes, 5.7% eosinophiles,
6.6% monocytes and 0.1% basophiles. Platelets count
was 793 × 109/l and hemoglobin 12.7 g/dl. Serum lactate
dehydrogenase (LDH) was 515 U/l (normal up to 480 U/
l), and serum alkaline phosphates was 120 U/l (normal:
up to 90 U/l).
Karyotyping was done again at 3 and 10 months after ini-
tiation of Imatinib-treatment, respectively, showing addi-
tional karyotypic changes. A complex karyotype 46, XX,
t(1;4;5;9;22) was determined in GTG-banding (Fig. 1)
and further studied by molecular cytogenetics (Fig. 2 and
Fig. 3). Dual-color-FISH using a commercially available
probe specific for BCR and ABL revealed that the typical
Philadelphia-chromosome with BCR/ABL-translocation
was present. However, parts of chromosome 22 were
present on a der(1) (Fig. 2). Thus, array-proven high-reso-
lution multicolor banding (aMCB, Fig. 3), using probes
for the corresponding chromosomes involved according
to GTG-banding, was done [11]. The following result was
obtained: 46, XX, t,(1;4;5;9;22)(q42;p14;q31;q34;q11.2).
Thus, it is most likely that the complexity of the karyotype
was missed initially due to low chromosomal resolution.
Discussion
According to the literature, in 2-10% CML cases the fusion
gene BCR/ABL is a result of a complex translocation. At
GTG-banding revealed a complex karyotype involving three  further chromosomes besides chromosomes 9 and 22 Figure 1
GTG-banding revealed a complex karyotype involv-
ing three further chromosomes besides chromo-
somes 9 and 22. All derivative chromosomes are marker 
by arrowheads.
Fluorescence in situ hybridization (FISH) using probes for  BCR (green) and ABL (red) confirmed an involvement of  chromosome 1 in the rearrangement present in this case Figure 2
Fluorescence in situ hybridization (FISH) using 
probes for BCR (green) and ABL (red) confirmed an 
involvement of chromosome 1 in the rearrangement 
present in this case. Abbreviations: # = chromosome; der 
= derivative chromosome; Ph = Philadelphia-chromosome.Molecular Cytogenetics 2009, 2:21 http://www.molecularcytogenetics.org/content/2/1/21
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present it appears that variant translocations can affect
any chromosome. However, it has been suggested that
distribution of the break-points is non-random with the
chromosomal bands most susceptible to breakage being:
1p36, 3p21, 5q31, 6p21, 9q22, 10q22, 11q13, 12p13,
17p13, 17q21, 17q25, 19q13, 21q22, 22q12 and 22q13
[7]. In our study we found one out of the three break-
points to be member of this list, i.e. 5q31. However, the
fusion gene remained on chromosome 22.
Two possible mechanisms for variant translocation for-
mation were suggested. The first is a single-event rear-
rangement via the simultaneous breakage of several
chromosomes followed by mismatched joining [12].
Nacheva et al proposed a classical Ph translocation fol-
lowed by a further translocation event between chromo-
somes 9 and 22 plus a third chromosome [13]. The
mechanism of the formation of a variant Ph translocation
may have prognostic importance in that a two-event
mechanism represents clonal evolution, whereas a variant
translocation occurring via a single genomic rearrange-
ment may confer a similar prognosis to the classical Ph
translocation; i.e. clonal evolution has a worse prognosis
[14]. According to that, we suggest that the reported
patient developed the rearrangement in one initial step
and thus, also had such a good response to treatment.
Materials and methods
Banding cytogenetics using GTG-banding was done
according to standard procedures [15]; 20 metaphases
derived from unstimulated bone marrow of the patient
were analyzed, each.
Fluorescence in situ hybridization (FISH) using commer-
cially available probes for BCR and ABL (Abbott/Vysis)
were applied according to manufacturers instructions.
High resolution array-proven multicolor-banding
(aMCB) based on microdissection derived region-specific
libraries for chromosome 1, 4, 5, 9 and 22 was done as
described before; method and MCB probe sets are speci-
fied [11,16]. 20 metaphase spreads were analyzed, each
using a fluorescence microscope (AxioImager.Z1 mot,
Zeiss) equipped with appropriate filter sets to discrimi-
nate between a maximum of five fluorochromes and the
counterstain DAPI (Diaminophenylindol). Image captur-
ing and processing were carried out using an Isis mFISH
imaging system (MetaSystems, Altlussheim, Germany) for
the evaluation MCB.
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Array-proven multicolor banding (aMCB) was applied to  determine the involved in this complex rearrangement Figure 3
Array-proven multicolor banding (aMCB) was 
applied to determine the involved in this complex 
rearrangement. In each lane the results of aMCB analysis 
using probe-sets for chromosomes 1, 4, 5, 9 and 22 are 
shown. The normal chromosomes are shown in the first col-
umn, the derivative of all five chromosomes in the following 
ones. In the light gray by aMCB-probes unstained regions on 
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